Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
New warning for off-label Fentora
The FDA issued a warning yesterday on Fentora, the Cephalon painkiller recently linked to three deaths. All three stemmed from off-label use of the fentanyl drug, which is approved only for treatment of breakthrough cancer pain.
Cephalon had warned doctors two weeks ago of the risk of fatal overdose with Fentora. But the company may have played a role in pushing off-label prescriptions. Since 2004, Cephalon has drawn scrutiny from state and federal prosecutors, and from a Congressional oversight committee, for allegedly promoting off-label uses of several drugs, including Fentora.
- see the FDA warning
- read the article from the Philadelphia Inquirer
Related Articles:
Red flags raised on Fentora misuse. Report
FDA approves Fentora for cancer pain. Report
Cephalon shares jump on Fentora decision. Report
Cephalon takes heat for off-label narcotic promotion. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
